SHIBA Mitutoshi Chiba University, Associate Professor, 医学部, 助教授 (20162620)
BABA Masayuki Chiba University, Lecturer, 医学部附属病院, 講師 (00143305)
FUJISAWA Takehiko Institute of Pulmonary Cancer Research, Chiba University School of Medicine, Pro, 医学部, 教授 (80110328)
|Budget Amount *help
¥3,000,000 (Direct Cost : ¥3,000,000)
Fiscal Year 1998 : ¥1,200,000 (Direct Cost : ¥1,200,000)
Fiscal Year 1997 : ¥1,800,000 (Direct Cost : ¥1,800,000)
Expression of matrix metalloproteinase (MMP) -2, MMP-9, tissue inhibitor of metalloproteinases (TIMP) -1, and TIMP-2 was studied in non small cell lung cancer (NSCLC). Activity of MMP-2 and MMP-9 by gelatin zymography and expression of MMP-2, MMP-9, TIMP-1, and TIMP-2 mRNAs were examined in 11 lung cancer cell lines which included six small cell lung cancer (SCLC) cell lines. Both cancer cell lines and NSCLC tumor samples frequently expressed MMP-2, MMP-9, TIMP-1, and TIMP-2, and MMP-2 in particular was highly expressed in malignant cells and surrounding fibroblasts. These findings suggest that MMP-2 plays a more important role in invasion of NSCLC than MMP-9 and that TIMP-2 may have clinical relevance in NSCLC.
Moreover we investigated the relationship between circulating plasma MMP-9, its expression in tumor samples and other clinical features in patients with non small cell lung cancer (NSCLC) Plasma MMP-9 concentrations were elevated in 4 5.2% of NSCLC patients, however, this elevation did not appear to correlate with MMP-9 production by cancer and stromal cells. We concluded that the MMP-9 enzyme linked immunosorbent assay (ELISA) could be a beneficial adjunct for assessing the tumor burden of NSCLC, especially types of squamous cell carcinoma and large cell carcinoma.